JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng upgraded Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and set a $5 price target.
March 19, 2024 | 9:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mersana Therapeutics was upgraded by JP Morgan from Underweight to Neutral with a new price target of $5.
Upgrades by major financial institutions like JP Morgan typically lead to positive short-term price movements. The upgrade from Underweight to Neutral suggests a more favorable outlook on MRSN by the analysts, potentially leading to increased investor confidence and buying activity. The set price target of $5 also provides a benchmark for investors, indicating the analyst's expectation of the stock's value, which can influence market perception and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100